The 5 constituents in the munKNEE Psychedelic Drug Stocks Index went down 1.6% the second week of December, on average, and are now down 11.5% YTD, on average.

Below is how they performed this week, in descending order.

1. Compass Pathways (CMPS): up 23.6%
   • is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
2. Mind Medicine (MNMD): up 4.4%
   • is primarily focused on the use of LSD and MNMA. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
3. Atai Life Sciences (ATAI): up 4.1%
   • is focused on the use of ketamine, DMT and ibogaine.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
   • Read: atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
4. GH Research (GHRS): down 6.5%
   • is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
5. Incannex Healthcare (IXHL): down 30.6%
   • is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.

Summary

The munKNEE Psychedelic Drug Stocks Index was down 1.6% this week and is now down 11.5% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, was up 3.8% but remains down 28.8% YTD.

More By This Author:

Canadian Cannabis LP Stocks Index Down 5% This Week - Here's Why
These 6 AI-Capable PC Stocks Should Rise Considerably In 2024/25
Get Invested Now: AI-Enabled PCs Are Coming In 2024